Article thumbnail

Pioglitazone improves visceral sensation and colonic permeability in a rat model of irritable bowel syndrome

By Tsukasa Nozu, Saori Miyagishi, Rintaro Nozu, Kaoru Takakusaki and Toshikatsu Okumura

Abstract

Visceral hypersensitivity and impaired gut barrier with minor inflammation are considered to play an important role in the pathophysiology of irritable bowel syndrome (IBS). Since pioglitazone is known to have anti-inflammatory property, we hypothesized that pioglitazone is beneficial for treating IBS. In this study, the effect was tested in rat IBS models such as lipopolysaccharide or repeated water avoidance stress-induced visceral allodynia and increased colonic permeability. Pioglitazone blocked these visceral changes, and GW9662, a peroxisome proliferator-activated receptor gamma (PPAR-γ) antagonist fully reversed the effect by pioglitazone. These results suggest that PPAR-γ activation by pioglitazone may be useful for IBS treatment. Keywords: Pioglitazone, Visceral sensation, Gut permeabilit

Topics: Therapeutics. Pharmacology, RM1-950
Publisher: Elsevier
Year: 2019
DOI identifier: 10.1016/j.jphs.2018.11.006
OAI identifier: oai:doaj.org/article:0e8a178d0209494ba5dd4de4480524e2
Journal:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • https://doaj.org/toc/1347-8613 (external link)
  • https://doaj.org/article/0e8a1... (external link)
  • http://www.sciencedirect.com/s... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.